NDAORALFOR SOLUTION
Approved
Jun 2009
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
4
Data completeness
7/8 — Comprehensive
CAMBIA (diclofenac potassium) by Medica Corp is analgesic, anti-inflammatory, and antipyretic properties. Approved for post-operative pain, ankle sprain. First approved in 2009.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAMBIA is an oral diclofenac potassium solution approved in 2009 for rapid pain relief and fever reduction. It works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes to suppress prostaglandin synthesis, thereby reducing pain, inflammation, and fever. The potassium salt formulation enables faster absorption compared to standard diclofenac formulations.
$2MPart D
LOE ApproachingDeclining
1mo to LOECAMBIA faces imminent generic competition with minimal claims volume, signaling a consolidating team structure and shift toward pipeline-focused roles.
Mechanism of Action
analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of Diclofenac Potassium, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro.…
Indications (2)
Worked on CAMBIA at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.